Biogen (BIIB) Competitors $119.26 +4.09 (+3.55%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. REGN, ALNY, UTHR, INCY, BMRN, EXEL, NBIX, EXAS, HALO, and MDGLShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Biogen vs. Regeneron Pharmaceuticals Alnylam Pharmaceuticals United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Biogen (NASDAQ:BIIB) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Is BIIB or REGN more profitable? Regeneron Pharmaceuticals has a net margin of 31.07% compared to Biogen's net margin of 16.87%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.87% 14.98% 8.76% Regeneron Pharmaceuticals 31.07%16.32%12.76% Does the MarketBeat Community believe in BIIB or REGN? Biogen received 266 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes181671.41% Underperform Votes72728.59% Regeneron PharmaceuticalsOutperform Votes155066.95% Underperform Votes76533.05% Do analysts recommend BIIB or REGN? Biogen presently has a consensus target price of $213.15, indicating a potential upside of 78.73%. Regeneron Pharmaceuticals has a consensus target price of $964.88, indicating a potential upside of 68.96%. Given Biogen's higher possible upside, research analysts plainly believe Biogen is more favorable than Regeneron Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 18 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.42Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.77 Do insiders & institutionals have more ownership in BIIB or REGN? 87.9% of Biogen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, BIIB or REGN? Biogen has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Which has higher valuation and earnings, BIIB or REGN? Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.80$1.63B$11.1910.66Regeneron Pharmaceuticals$14.20B4.40$4.41B$38.2814.92 Does the media refer more to BIIB or REGN? In the previous week, Regeneron Pharmaceuticals had 10 more articles in the media than Biogen. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 35 mentions for Biogen. Regeneron Pharmaceuticals' average media sentiment score of 1.14 beat Biogen's score of 0.95 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 21 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 31 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Positive SummaryRegeneron Pharmaceuticals beats Biogen on 15 of the 19 factors compared between the two stocks. Remove Ads Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.46B$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio10.6630.3721.6517.79Price / Sales1.80438.12376.3294.47Price / Cash6.09168.6838.1534.64Price / Book1.043.456.443.99Net Income$1.63B-$72.06M$3.20B$247.24M7 Day Performance0.06%4.36%6.67%5.84%1 Month Performance-14.47%-17.35%-6.27%-5.78%1 Year Performance-39.82%-31.05%8.56%-1.99% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.6979 of 5 stars$119.26+3.6%$213.15+78.7%-39.8%$17.46B$9.68B10.668,720REGNRegeneron Pharmaceuticals4.8749 of 5 stars$565.48-1.4%$966.88+71.0%-36.9%$61.51B$14.20B14.7011,900Analyst ForecastPositive NewsALNYAlnylam Pharmaceuticals4.5031 of 5 stars$231.24-1.9%$316.25+36.8%+61.6%$30.04B$2.25B-106.412,000UTHRUnited Therapeutics4.9044 of 5 stars$287.85-1.6%$388.25+34.9%+22.2%$12.95B$2.88B12.66980Positive NewsINCYIncyte4.8353 of 5 stars$59.51-1.8%$74.88+25.8%+10.0%$11.46B$4.24B219.392,320BMRNBioMarin Pharmaceutical4.8914 of 5 stars$57.44-4.7%$94.00+63.6%-35.3%$10.89B$2.85B25.953,401Gap UpEXELExelixis4.256 of 5 stars$34.41-0.5%$37.59+9.3%+56.7%$9.58B$2.17B19.341,220Positive NewsGap DownNBIXNeurocrine Biosciences4.8404 of 5 stars$92.44-3.4%$163.52+76.9%-29.5%$9.19B$2.36B28.021,200Analyst UpgradeNews CoveragePositive NewsGap UpEXASExact Sciences4.2313 of 5 stars$45.01+5.8%$70.26+56.1%-38.0%$8.30B$2.76B-8.036,400HALOHalozyme Therapeutics4.3931 of 5 stars$58.77-1.7%$62.78+6.8%+59.0%$7.23B$1.02B17.07390Positive NewsMDGLMadrigal Pharmaceuticals4.0512 of 5 stars$309.86-1.4%$378.44+22.1%+36.2%$6.79B$180.13M-12.2690News CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Neurocrine Biosciences Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
